Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
// Carrie A. Duckworth 1, * , Scott E. Guimond 2, * , Paulina Sindrewicz 1 , Ashley J. Hughes 2, 4 , Neil S. French 3 , Lu-Yun Lian 2 , Edwin A. Yates 2 , D. Mark Pritchard 1 , Jonathan M. Rhodes 1 , Jeremy E. Turnbull 2 , Lu-Gang Yu 1 1 Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 2 Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom 3 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 4 Diamond Light Source Ltd, Harwell Innovation Campus, Didcot, United Kingdom * These authors have contributed equally to this work Correspondence to: Lu-Gang Yu, e-mail: lgyu@liv.ac.uk Jeremy E. Turnbull, e-mail: j.turnbull@liv.ac.uk Keywords: galectin-3, metastasis, heparin Received: September 29, 2014 Accepted: June 12, 2015 Published: June 23, 2015 ABSTRACT Concentrations of circulating galectin-3, a metastasis promoter, are greatly increased in cancer patients. Here we show that 2- or 6-de- O -sulfated, N -acetylated heparin derivatives are galectin-3 binding inhibitors. These chemically modified heparin derivatives inhibited galectin-3-ligand binding and abolished galectin-3-mediated cancer cell-endothelial adhesion and angiogenesis. Unlike standard heparin, these modified heparin derivatives and their ultra-low molecular weight sub-fractions had neither anticoagulant activity nor effects on E-, L- or P-selectin binding to their ligands nor detectable cytotoxicity. Intravenous injection of such heparin derivatives (with cancer cells pre-treated with galectin-3 followed by 3 subcutaneous injections of the derivatives) abolished the circulating galectin-3-mediated increase in lung metastasis of human melanoma and colon cancer cells in nude mice. Structural analysis using nuclear magnetic resonance and synchrotron radiation circular dichroism spectroscopies showed that the modified heparin derivatives bind to the galectin-3 carbohydrate-recognition domain. Thus, these chemically modified, non-anticoagulant, low-sulfated heparin derivatives are potent galectin-3 binding inhibitors with substantial potential as anti-metastasis/cancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Systems Biology Approach for the Investigation of the Heparin/Heparan Sulfate Interactome
Ori, A., Wilkinson, M. C., & Fernig, D. G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228114 · Cited by 251 · cited 1×
“Part of the unpredictability is believed to derive from the “nonspecific” effects of UFH on a wide variety of cellular processes as a result of its interactions with many plasma and cellular proteins due in part to its high charge [21], and its ability to mimic heparan sulphate and interact with complex signalling net…”
Cited by
Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics
Karamanos, N. K., Piperigkou, Z., Theocharis, A. D., Watanabe, H., Franchi, M., Baud, S., Brézillon, S., Götte, M., Passi, A., Vigetti, D., et al. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00354 · Cited by 367
Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
Suthahar, N., Meijers, W. C., Silljé, H. H. W., Ho, J. E., Liu, F.-T., & de Boer, R. A. (2018) · Theranostics · doi:10.7150/thno.22196 · Cited by 309
New Applications of Heparin and Other Glycosaminoglycans
Lima, M., Rudd, T., & Yates, E. (2017) · Molecules · doi:10.3390/molecules22050749 · Cited by 89
Self-citationReview of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
Al Attar, A., Antaramian, A., & Noureddin, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1894127 · Cited by 47
“tion in lung metastasis of human melanoma and colon cancer cells by inhibiting Gal-3 ligand binding [59].”
BackgroundTalaga, M. L., Fan, N., Fueri, A. L., Brown, R. K., Bandyopadhyay, P., & Dam, T. K. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00504 · Cited by 44
Metadata
- Authors
- Duckworth, C. A., Guimond, S. E., Sindrewicz, P., Hughes, A. J., French, N. S., Lian, L.-Y., Yates, E. A., Pritchard, D. M., Rhodes, J. M., Turnbull, J. E., & Yu, L.-G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-06-23
- Volume
- 6
- Issue
- 27
- Pages
- 23671-23687
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2130812849
- Cited by
- 53
- References
- 1
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.